ARTICLE | Company News
Opko, Redox Pharmaceutical Corp. deal
June 16, 2008 7:00 AM UTC
Opko acquired exclusive, worldwide rights from Redox to develop and commercialize Doxovir ( CTC-96) for ophthalmic indications. The compound has completed Phase I trials to treat viral conjunctivitis...